Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Research reports on breast cancer from University of Vermont provide new insights
June 5th, 2008
According to a study from the United States, " National Cancer Institute of Canada Clinical Trials Group trial MA. 17 randomly assigned 5,187 postmenopausal, hormone-receptor-positive patients with early breast cancer who completed 5 years of tamoxifen to receive either letrozole or placebo. At 30 months median follow-up, letrozole significantly improved disease-free survival (DFS) in all patients and overall survival (OS) in node-positive patients." "Breast cancer incidence increases with age and more than 1,300 women age 70 years or older were enrolled onto MA. 17, making it ideal to explore the benefits, toxicities, and quality of life (QOL) impact of letrozole on...
Source: Women's Health Weekly (2008-06-05)
|
